Metraipolis › archive › dc_56ac84d9bf44

VEGF-inhibitor switch trial in poor-responsive neovascular age-related macular degeneration: assessing brolucizumab vs. faricimab: VISTA study — Europe PMC PMID:41524752

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41524752
DOI
10.1007/s00417-[numero omesso]-2
License (as archived)
solo-consultazione
Archived
2026-11-06T21:35:42.370Z
SHA-256 of the archived text
028b1a2560a5f29ff2fd64607764ab806bfd97bea29c562582502ac8afb27263
Stable URL of this page
https://metraipolis.com/documento/dc_56ac84d9bf44

How to cite

VEGF-inhibitor switch trial in poor-responsive neovascular age-related macular degeneration: assessing brolucizumab vs. faricimab: VISTA study — Europe PMC PMID:41524752 — Europe PMC (en), https://europepmc.org/article/MED/41524752 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_56ac84d9bf44 (Metraipolis archive dc_56ac84d9bf44, sha256 028b1a2560a5f29ff2fd64607764ab806bfd97bea29c562582502ac8afb27263)
BibTeX
@misc{dc56ac84d9bf44,
  title = {VEGF-inhibitor switch trial in poor-responsive neovascular age-related macular degeneration: assessing brolucizumab vs. faricimab: VISTA study — Europe PMC PMID:41524752},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41524752},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_56ac84d9bf44; sha256 028b1a2560a5f29ff2fd64607764ab806bfd97bea29c562582502ac8afb27263},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41524752. Agents can read the archived copy with the MCP tool read_document.